FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 大成生化科技集團有限公司 呈交日期： 2025年10月2日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | | 00809 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED 大 成 生 化 科 技 集 團 有 限 公 司 * （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：00809） 完成根據特別授權發行代價股份 及 於完成後，總額約人民幣461.1百萬元的供應商債務（經整體折減約34.72%後，最終金額 為人民幣301,007,373元）已悉數資本化。目標公司成為本公司的直接全資附屬公司，而 世紀大成再次成為本公司的間接全資附屬公司。為免生疑問，於供應商債務重組安排過 程中，世紀大成的財務業績、資產及負債一直併入本公司的綜合財務報表。有關供應商 債務重組安排的詳情，請參閱該通函。 轉換可換股債券 轉換可換股債券 完成根據特別授權發行代價股份 茲提述大成生化科技集團有限公司（「本公司」）日期為二零二五年七月八日之公告及本公 司日期為二零二五年八月二 ...

致：香港交易及結算所有限公司 公司名稱: 大成生化科技集團有限公司 呈交日期: 2025年10月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00809 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.1 | HKD | | 3,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 30,000,000,000 | HKD | | | 0.1 HKD | | 3,000,000,000 | | 2. 股份分類 | 優先股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 否 | | | --- ...

（ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：00809） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED 大 成 生 化 科 技 集 團 有 限 公 司 * 於股東特別大會上 提呈決議案的投票結果 董事會欣然宣佈，於股東特別大會上提呈的普通決議案已以按股數投票方式正式通 過。 謹此提述大成生化科技集團有限公司（「本公司」）於二零二五年八月二十九日刊發的通函 （「該通函」）。除文義另有所指外，本公告所用詞彙與該通函所界定者具有相同涵義。 於股東特別大會上的投票結果 董事會欣然宣佈，載列於日期為二零二五年八月二十九日的股東特別大會通告（「股東特 別大會通告」）的普通決議案（「決議案」）投票結果如下： — 1 — | 決議案 | 實際投票票數(%) | | | --- | --- | --- | | | 贊成 | 反對 | | ...

[Definitions](index=3&type=section&id=Definitions) This section defines key terms and entities used in the report, crucial for understanding the company's operations, financial transactions, and corporate governance - “The Company” refers to DaCheng Biochemical Technology Group Limited, a limited company incorporated in the Cayman Islands, whose shares are listed on the Main Board of the Stock Exchange (stock code: **00809**)[6](index=6&type=chunk) - “Disposal” refers to the sale of the disposed shares in accordance with the terms of the sale and purchase agreement, which was completed on **December 30, 2024**[9](index=9&type=chunk) - “Supplier Debt Restructuring Arrangement” refers to a series of arrangements undertaken or to be undertaken by the Group to restructure and settle supplier debts, totaling approximately **RMB 461.1 million**[13](index=13&type=chunk) [Company Information](index=10&type=section&id=Company%20Information) This section lists the company's board members, company secretary, registered office, principal place of business in Hong Kong, auditor, legal counsel, principal bankers, share registrar, Hong Kong share registrar, website, and stock code - This section lists the company's board members, company secretary, registered office, principal place of business in Hong Kong, auditor, legal counsel, principal bankers, principal share registrar, Hong Kong share registrar, website, and stock code[16](index=16&type=chunk)[17](index=17&type=chunk) - Board members include Executive Directors Mr. Wang Cheng (Chairman) and Mr. Wang Guicheng, Non-executive Director Mr. Li Yuewen, and Independent Non-executive Directors Ms. Jiang Fangfang, Mr. Tan Chao, and Ms. Xie Liangqiu[16](index=16&type=chunk) - The Company's stock code is **00809**, and its auditor is RSM Hong Kong[16](index=16&type=chunk)[17](index=17&type=chunk) [Letter to Shareholders](index=11&type=section&id=Letter%20to%20Shareholders) [3.1 Business Review](index=11&type=section&id=3.1%20Business%20Review) Following structural reorganization, the Group optimized resource allocation, significantly enhancing Changchun Deda's production facility utilization and reducing operating costs. The amino acid business performed strongly, achieving over **30% year-on-year growth in consolidated revenue** through flexible production and build-to-order strategies. Despite pressure on lysine product average selling prices, production cost reductions outpaced price declines, leading to a substantial increase in gross profit margin - The Group's amino acid business performed strongly, maintaining high production capacity utilization and flexibly adjusting production lines to produce based on sales, shortening finished goods inventory time and reducing losses[18](index=18&type=chunk) - Despite intense domestic competition leading to downward pressure on the average selling price of lysine products, the Group focused on expanding sales volume, resulting in a **year-on-year increase of over 30% in consolidated revenue** for the period[18](index=18&type=chunk) - The Group accurately anticipated rising corn prices and promptly implemented inventory measures, coupled with energy-saving and consumption-reducing production processes, leading to a greater reduction in production costs than the decline in product prices, thereby improving operational efficiency[18](index=18&type=chunk) Gross Profit and Gross Profit Margin Changes | Metric | H1 2025 | H1 2024 | | :--- | :--- | :--- | | Gross Profit | Substantial increase of nearly **1.5 times** | - | | Gross Profit Margin | **13.6%** | **7.3%** | - Following the completion of the Disposal on **December 30, 2024**, administrative and other expenses of the disposed group are no longer consolidated into the financial statements, reducing overall operating costs and increasing cash liquidity[19](index=19&type=chunk) - The Group has reached a consensus with over **130 suppliers** regarding payables of approximately **RMB 461.1 million**, with the supplier debt restructuring arrangement expected to be completed within the year, further improving the financial position[19](index=19&type=chunk) [3.2 Future Outlook](index=12&type=section&id=3.2%20Future%20Outlook) Facing global economic uncertainties, tariff pressures, rising domestic corn prices, and new lysine production capacity, the Group will initiate a boiler renovation project to reduce costs, promote full resumption of operations at Xinglongshan plant, and explore business alliances or investor participation, while monitoring the expropriation of remaining Luyuan properties to overcome debt crises and achieve stable business development - Despite cross-border trade expansion in the **first half of 2025**, the global economic outlook remains clouded by tariffs, with global growth expected to be uncertain in the **second half of 2025**[20](index=20&type=chunk) - The market anticipates continued increases in corn prices in the **second half of 2025**, potentially impacting the Group's production costs; the domestic lysine market is expected to see hundreds of thousands of tonnes of new capacity, reshaping the competitive landscape[20](index=20&type=chunk) - The Group has initiated a boiler renovation project aimed at effectively reducing Changchun Deda's operating costs and enhancing production facility efficiency[21](index=21&type=chunk) - The Group is committed to promoting the full resumption of operations at the Xinglongshan plant, including exploring the introduction of business alliances or investors to participate in operations, and utilizing R&D centers and pilot facilities to explore strategic cooperation opportunities[21](index=21&type=chunk) - The Group will continue to monitor the expropriation of remaining Luyuan properties and ensure the disposed group repays the outstanding portion of the repurchase loan, significantly reducing financial expenditures, improving overall financial health, and gradually overcoming the debt crisis[21](index=21&type=chunk) [Management Discussion and Analysis](index=13&type=section&id=Management%20Discussion%20and%20Analysis) [4.1 Business Review](index=13&type=section&id=4.1%20Business%20Review) The Group primarily engages in the production and sale of corn refined products and amino acids. Amid a slowing global economy, trade tensions, and geopolitical uncertainties, China's economy maintained stable growth but faced challenges. International corn prices fell, while domestic prices rose. The lysine market experienced significant volatility due to international trade policies, leading to decreased export volumes and domestic price pressure. The Group achieved significant growth in amino acid revenue and gross profit by strengthening domestic sales, developing new markets, and introducing high-value-added products, while restarting the boiler renovation project to enhance competitiveness and actively promoting the resumption of operations at the Xinglongshan plant and strategic collaborations - The Group primarily engages in the production and sale of corn refined products and amino acids (after the completion of the Disposal, it no longer operates corn sweetener and biochemical alcohol businesses)[24](index=24&type=chunk) - Global economic growth is projected to slow to **2.3% in 2025**, the lowest level since **2008**, facing challenges from trade tensions, geopolitical uncertainties, and protectionism[25](index=25&type=chunk) - China's GDP grew by **5.3% year-on-year** in the **first half of 2025**, with a stable economy but facing weak consumer confidence, the US-China trade war, real estate market adjustments, and external demand uncertainties[25](index=25&type=chunk) Corn Price Changes | Metric | January 2025 | End of June 2025 | End of June 2024 | | :--- | :--- | :--- | :--- | | International Corn Price (per bushel) | **459.2 US cents** | **420.5 US cents** | **397.0 US cents** | | Domestic Corn Price (per tonne) | **RMB 2,075** | **RMB 2,447** | - | - The global lysine market faced significant volatility, impacted by additional US tariffs and anti-dumping investigations by the EU and Brazil, leading to a **5.0% decrease in China's lysine export volume** to approximately **521,500 tonnes** in the **first half of 2025**[28](index=28&type=chunk) Changes in Average Price of China's Lysine Products | Period | Average Price (per tonne) | | :--- | :--- | | H1 2025 | **RMB 7,700 to RMB 8,100** (Decrease **23%-27%**) | | End of June 2024 | **RMB 10,200 to RMB 10,500** | - The Group strengthened domestic market sales and developed new non-EU markets, launching various new amino acid products with higher profit margins, resulting in significant growth in amino acid segment revenue and gross profit[29](index=29&type=chunk) - The boiler renovation project restarted and commenced construction in **July 2025**, expected to further reduce amino acid production costs and enhance market competitiveness[29](index=29&type=chunk) - The Group is actively committed to resuming production at the Xinglongshan plant, exploring the introduction of business alliances or investors, and collaborating on operating a synthetic biology pilot platform to enhance operational efficiency and strengthen working capital[29](index=29&type=chunk) [4.2 Financial Performance](index=14&type=section&id=4.2%20Financial%20Performance) The Group's financial performance for the period showed a **significant 32.0% increase in consolidated revenue**, with substantial improvements in gross profit and gross profit margin, driven by enhanced production facility utilization and reduced unit production costs, despite a decline in average selling prices for amino acid products. However, the company still recorded a net loss due to the absence of one-off government grants and fair value gains on financial assets from the prior period. Administrative and other expenses significantly decreased following the disposal of the disposed group, but finance costs rose due to increased estimated interest on convertible bonds [4.2.1 Consolidated Revenue and Gross Profit](index=14&type=section&id=4.2.1%20Consolidated%20Revenue%20and%20Gross%20Profit) Consolidated revenue for the period **increased significantly by approximately 32.0% to approximately HKD 1,186 million**, primarily due to improved utilization of amino acid production facilities and a decrease in average unit production costs, despite a decline in average selling prices for amino acid products, with gross profit and gross profit margin also showing significant improvement - The average selling price of amino acid products decreased by **11.9%** during the period, but the utilization rate of amino acid production facilities increased, and the total average unit production cost decreased by **18.4%**[30](index=30&type=chunk) Consolidated Revenue, Gross Profit, and Gross Profit Margin Changes | Metric | H1 2025 | H1 2024 | | :--- | :--- | :--- | | Consolidated Revenue | **HKD 1,186 million** (Increase **32.0%**) | **HK

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 公司名稱: 大成生化科技集團有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00809 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.1 | HKD | | 3,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 30,000,000,000 | HKD | | | 0.1 HKD | | 3,000,00 ...

Core Viewpoint - Dachen Biotech (00809.HK) reported a revenue of HKD 1.186 billion for the six months ending June 30, 2025, representing a year-on-year increase of 32% [1] Financial Performance - Revenue reached HKD 1.186 billion, up 32% year-on-year [1] - Gross profit amounted to HKD 161 million, reflecting a significant increase of 144.2% year-on-year [1] - Loss attributable to owners of the company was HKD 155 million, slightly improved from a loss of HKD 158 million in the same period last year [1] - Basic loss per share was HKD 0.017 [1]

大成生化科技(00809)发布截至2025年6月30日止6个月中期业绩，集团收益11.86亿港元，同比增长 31.99%;净亏损1.55亿港元，同比收窄1.91%;每股亏损1.7港仙。 ...

智通财经APP讯，大成生化科技(00809)发布截至2025年6月30日止6个月中期业绩，集团收益11.86亿港 元，同比增长31.99%;净亏损1.55亿港元，同比收窄1.91%;每股亏损1.7港仙。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED 大 成 生 化 科 技 集 團 有 限 公 司 * （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：00809） 截至2025年6月30日止六個月 中期業績公告 於2025年6月30日 | | | 2025年 | 2024年 | | --- | --- | --- | --- | | | | 6月30日 | 12月31日 | | | | （未經審核） | （經審核） | | | 附註 | 千港元 | 千港元 | | 非流動資產 | | | | | 物業、廠房及設備 | 10 | 2,146,691 | 2,119,050 | | 使用權資產 | | 292,875 | 290,085 | | 無形資產 | | 2,047 | 2,047 | | 按公允值計入損益（「按公允值計入損 ...